App More Accurate than Patient Evaluation of Stool Samples

An innovative mobile phone application was found to be as good as expert gastroenterologists at characterizing stool specimens, according to a study by Cedars-Sinai. The artificial intelligence (AI) used in the smartphone app also outperformed reports by patients describing their stool specimens.

Stool reporting by patients, usually guided by the Bristol Stool Scale, is crucial to helping physicians evaluate symptoms for diagnosis or for judging the effectiveness of medications.

"Sometimes patients don’t know what is normal or abnormal when trying to characterize a bowel movement. This app takes out the guesswork by using AI, not patient input, to process the images taken by the smartphone," said principal investigator of the study Mark Pimentel, MD, executive director of the Medically Associated Science and Technology Program at Cedars-Sinai.

"The mobile app produced more accurate and complete descriptions of constipation, diarrhea and normal stools than a patient could and was comparable to specimen evaluations by well-trained gastroenterologists in the study," said Pimentel, a specialist in irritable bowel syndrome (IBS).

The validation study, was published in the American Journal of Gastroenterology and will be presented at the Digestive Disease Week conference in San Diego on May 21.

Investigators used a trained AI app for smartphones developed by Dieta Health, a graduate of the Cedars-Sinai Accelerator program that helps entrepreneurs bring their innovative healthcare technology products to market. In a randomized controlled study, participants with diarrhea-predominant IBS, or IBS-D, were asked to use the AI app to take a picture of every stool for two weeks. In addition to the commonly used Bristol Stool Scale, the AI app also incorporates additional classification parameters. Two expert gastroenterologists assessed the images to validate the mobile app.

"The artificial intelligence tool removes the subjective description that can be part of a patient's description of their bowel specimens. In addition to improving a physician's ability to assess their patients' digestive health, this app could be advantageous for clinical trials by reducing the variability of stool outcome measures," said Ali Rezaie, MD, co-author of the study and the medical director of GI Motility at Cedars-Sinai.

Pimentel M, Mathur R, Wang J, Chang C, Hosseini A, Fiorentino A, Rashid M, Pichetshote N, Basseri B, Treyzon L, Chang B, Leite G, Morales W, Weitsman S, Kraus A, Rezaie A.
A Smartphone Application Using Artificial Intelligence Is Superior to Subject Self-Reporting When Assessing Stool Form.
Am J Gastroenterol. 2022 Mar 14. doi: 10.14309/ajg.0000000000001723

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...